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Summary 
Polygenic risk scores obtained as a weighted sum of associated variants can be used to 
explore association in additional data sets and to assign risk scores to individuals. The 
methods used to derive polygenic risk scores from common SNPs are not suitable for 
variants detected in whole exome sequencing studies. Rare variants which may have major 
effects are seen too infrequently to judge whether they are associated and may not be 
shared between training and test subjects. A method is proposed whereby variants are 
weighted according to their frequency, their annotations and the genes they affect. A 
weighted sum across all variants provides an individual risk score. Scores constructed in this 
way are used in a weighted burden test and are shown to be significantly different between 
schizophrenia cases and controls using a five-way cross validation procedure. This 
approach represents a first attempt to summarise exome sequence variation into a summary 
risk score, which could be combined with risk scores from common variants and from 
environmental factors. It is hoped that the method could be developed further. 
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Introduction 
Polygenic scores have found widespread application since they were used in a GWAS of 
schizophrenia (Purcell et al., 2009). In this study, very large numbers of variants showing 
weak association signals in a training set of cases with schizophrenia and controls were 
used to produce a score which was higher in a test set of cases with schizophrenia than 
controls and was also increased in subjects with bipolar disorder. As noted previously, the 
two main functions of the polygenic score are to demonstrate that variants selected from the 
training set are associated with the trait in the test set and to provide an overall assessment 
of an individual’s genetic risk (Dudbridge, 2013). The score consists of a weighted sum of 
the scores of the variant alleles possessed by the test subject. Different methods can be 
used to select the variants to be included and to assign their weights (Euesden et al., 2015). 
A key feature is that a large number variants is used and it is understood that many will not 
in fact be truly associated with the trait. As the sample size for the training set increases, so 
does the power to distinguish the truly associated variants and hence the polygenic score 
can become a more accurate determinant of genetic risk. 
Recently, association studies have been carried out involving whole exome sequencing of 
thousands of subjects. For non‑Mendelian diseases it is expected that there will be 
contributions to genetic risk from a number of different loci but it is not straightforward to 
obtain polygenic scores using a process similar to that which is appropriate for GWAS SNPs. 
There are several of reasons for this. One is that exome sequencing detects a very large 
number of variants and that rare variants tend to have weaker LD relationships than 
common SNPs, meaning that the number of independent signals is greater. However the 
main problem is that very rare variants may have major effects on risk but that they are so 
infrequent that there is very little information as to which variants are individually associated. 
A recent exome‑sequencing study of schizophrenia concluded that singleton variants, 
observed only in one study subject and never in ExAC, did have major effects (Genovese et 
al., 2016). One could never hope to derive a polygenic score using such variants because 
one could never know if a specific singleton variant had an effect or not and even if it did one 
would not expect to see it in a test subject. Another difference between GWAS SNPs and 
exome sequence variants is that the latter have a higher intrinsic information content. Some 
GWAS SNPs may be identified as being associated with gene expression but for many 
SNPs one can make only weak inferences about likely effect and one may not even know 
which gene is functionally relevant. However, an exome variant can be annotated and one 
can make reasonable predictions about which gene is likely to be affected and the nature of 
the effect. It would be desirable to incorporate such information into a score designed to 
reflect genetic risk. 
Overall, it seems that a polygenic risk score derived from exome sequence variants should 
be able to utilise variants which have not been seen in the training set but which are, in 
some defined way, similar to them. It will be expected that the risk score will make use of 
information about the likely effect of the variant and about the gene or type of gene which it 
affects. Such a scheme was devised and applied to the schizophrenia case‑control dataset. 
Methods 
Exome sequence data 
The data analysed consisted of whole exome sequence variants downloaded from dbGaP 
from a Swedish schizophrenia association study containing 4968 cases and 6245  controls 
(Genovese et al., 2016). The original analysis demonstrated that there was an excess of 
damaging ultra‑rare variants among cases, concentrated in particular gene sets. This 
sample included the 2545 cases and 2545 controls used for previously reported exome 
sequence association studies (Curtis, 2016, 2013; Purcell et al., 2014). The dataset was 
managed and annotated using the GENEVARASSOC program which accompanies 
SCOREASSOC (https://github.com/davenomiddlenamecurtis/geneVarAssoc). Version hg19 
of the reference human genome sequence and RefSeq genes were used to select variants 
on a gene‑wise basis.  
A number of QC processes were applied. Variants were excluded if they did not have a 
PASS in the information field and individual genotype calls were excluded if they had a 
quality score less than 30. Variants were also excluded if there were more than 10% of 
genotypes missing or of low quality in either cases or controls or if the heterozygote count 
was smaller than both homozygote counts in both cohorts. A preliminary weighted burden 
test analysis using variants with MAF<0.01 was carried out using SCOREASSOC (Curtis, 
2012). This identified several genes which had a significant excess of rare, functional 
variants in cases but on closer examination it emerged that these results were driven by 
variants which were reported in ExAC to have a markedly different allele frequency in 
Finnish as opposed to non‑Finnish Europeans (Lek et al., 2016). In order to address this 
issue we set out to identify those subjects who appeared to have a substantial Finnish 
component to their ancestry. To do this, for each subject the genotype of the variant with the 
highest MAF in each of 18349 genes was used to calculate an odds ratio based on the 
Finnish versus non‑Finnish European allele frequencies presented in ExAC r.03. The logs of 
these odds ratios were then summed to produce a measure denoted as the F score. The 
distributions of the F scores in cases and controls were plotted and each distribution was 
mostly normally distributed but had an extended right tail, indicating that a proportion of both 
cases and controls were likely to have substantial Finnish ancestry. The right tail was larger 
in the cases and overall the cases had significantly higher F scores than controls (t=16.4, 
df=11212, p=2.2e‑16). Overall the mean F score was ‑13.0 with SD 24.3. A cut‑off value of 
10 was chosen to exclude the right tails, and subjects with a higher score were removed, 
comprising 743 cases and 411 controls. When the gene‑wise weighted burden tests were 
repeated on the reduced sample of 4225 cases and 5834 controls the previous anomalous 
results did not recur and the tests generally conformed with the expected null hypothesis 
distribution. It thus appeared that this process had produced a more homogeneous dataset 
which was used in the subsequent analyses. 
Risk score overview 
In order to construct an exome‑wide risk score the aim was to follow the approach 
implemented in SCOREASSOC and provide a weight for each variant based on its 
frequency and predicted function (Curtis, 2012). Thus, subjects with more rare, functional 
variants would receive higher scores. A gene‑wise risk score is derived as the sum of the 
variant‑wise weights, each multiplied by the number of alleles of the variant which a given 
subject possesses. If a single set of weights is used then this approach produces a test for 
association in which the asymptotic p values conform closely with those obtained from 
permutation testing (Curtis, 2016). An exome‑wide risk score can be derived as the weighted 
sum of gene‑wise scores, with some genes being weighted more highly than others. 
Potentially such a model has a large number of parameters because a different weight can 
be assigned to each variant and to each gene. 
Variant weighting 
Each variant was annotated using VEP, PolyPhen and SIFT (McLaren et al., 
2016)(Adzhubei et al., 2013; Kumar et al., 2009). VEP produces annotations for 36 different 
possible types of variant. In order to reduce the parameter space, each variant type was 
characterised according to whether each of seven attributes was applicable to it, these 
attributes being: possibly having a non‑coding effect through being in a regulatory region or 
intronic; in UTR; in coding region; nonsynonymous; loss of function; possibly or probably 
damaging according to PolyPhen; deleterious according to SIFT. Table 1 shows the list of 
VEP annotation types along with which attributes would be applicable to each. Each attribute 
would be assigned a weight and then the weight for a particular variant would consist of the 
sum of weights of its applicable attributes. A background weight for the attribute "any variant" 
would also be assigned, meaning that in all a total of eight attribute weights could be used to 
generate functional weights for all variants. So, for example, the weight for a variant 
annotated as 5' UTR would be the sum of three weights for any variant, possible non‑coding 
effect and UTR. 
For a general application, the weight for each variant would also be multiplied by a factor 
based on its frequency, with rarer variants being given higher weight. However previous 
research has made it clear that there are no common variants with a substantial effect on 
risk of schizophrenia and hence it was decided to restrict attention to variants with MAF of 
0.01 or less in either cases or controls. In these circumstances the weighting scheme based 
on frequency as implemented in SCOREASSOC would have had a negligible effect in terms 
of distinguishing between rare and extremely rare variants and so no frequency‑based 
weighting was applied. Applying the above QC processes and allele frequency restriction 
yielded genotypes for 1,177,741 variants in 19,627 genes. 
Gene weighting 
In principle, with improved knowledge about the genetic contribution to schizophrenia risk it 
would be possible to assign weights to individual genes. At present it is not clear which 
individual genes are involved or the magnitude of their associated risks. However previous 
work has proposed sets of genes which may be enriched for rare, functional variants in 
schizophrenia cases (Curtis, 2016; Genovese et al., 2016; Purcell et al., 2014). The lists of 
genes for the gene sets tested for enrichment in the original analysis of this dataset are 
shown in Table 2. In addition to these, a set was created of which all genes were a member. 
Rather than assign a weight to each gene separately, a weight could be assigned to each 
gene set and then the weight for a gene could be defined as the sum of the weights of all the 
gene sets of which it was a member.  
Matrix notation 
With this approach in mind, an overall risk score can be calculated as the product of a 
number of matrices, as follows: 
A is a matrix which defines which attributes are possessed by each variant. It has columns 
equal to NVar, the number of variants, and rows equal to NAttrib, the number of attributes, here 
8. Aij is 1 or 0, depending on whether the jth variant has the ith attribute. 
F is diagonal matrix with NVar rows and columns. The diagonal elements consist of weights 
derived from the allele frequency so that variants with high MAF have a weight close to 1 
and rare variants have a weight close to an arbitrarily chosen weighting factor, as 
implemented in SCOREASSOC and as described previously (Curtis, 2012). As stated 
above, this weighting was not applied for the current analyses, equivalent to setting all 
diagonal elements to 1. 
I is the indicator matrix which codes the subject genotype at each variant. It is a diagonal 
matrix with NVar rows and columns and the diagonal elements consist of 0, 1 or 2 depending 
on how many copies of the minor allele of the variant the subject possesses. If a subject had 
an unknown genotype they would be assigned a value of 2xMAF. 
G is a matrix with NVar rows and number of columns equal to NGene, the number of genes 
tested. Gij is 1 if the ith variant is in the jth gene, with the other elements of the row being 0. 
Variants were extracted and dealt with one gene at a time and each variant was assigned to 
the gene for which it was extracted. Since for each gene all variants were extracted between 
the transcription start and end sites, a small number of variants in overlapping genes would 
have been extracted twice and would be dealt with as two different variants, each assigned 
to a different gene.  
S is a matrix with NGene rows and number of columns equal to NSet, the number of gene sets 
used. Sij is 1 if the ith gene is a member of the jth gene set and 0 otherwise. Since a gene 
can be a member of more than 1 set, there could be several 1 values in each row.  
WAtt is a row vector with NAtt elements providing the weights for each attribute. 
WSet is column vector with NSet elements providing the weights for each gene set. 
Using this notation, the overall risk score R for a subject is given by: 
R = WAtt x A x F x I x G x S x WSet 
Only the values for elements of I differ between subjects. 
In order to allow rapid recalculation of the risk score for different values of the weights for the 
gene sets and variant attributes, it is helpful to calculate for each subject an intermediate 
matrix D with NSet columns and NAtt rows which contains a summary of aggregate scores by 
gene set and attribute so that we have: 
D = A x F x I x G x S 
R = WAtt x D x WSet 
Practical implementation 
In order to implement this system in practice the following procedure was applied. VEP, SIFT 
and PolyPhen annotations were obtained for all the variants in the case‑control VCF file. 
GENEVARASSOC was used to extract the genotypes for variants one gene at a time and 
used the annotations to provide a code for each variant consisting of a binary number 
denoting the attributes which were applicable to that variant. That is, attributes were 
numbered consecutively from 1 and if attribute i was applicable to the variant then one would 
add 2i to the code. Using this scheme, a variant with the second and third attributes would 
have a weight of 110 in binary notation, i.e. 6. Next, a custom‑written program was used to 
produce aggregate attribute scores from the variant scores by decoding the weight to 
determine which attributes were applicable to each variant. At this stage, weighting for 
frequency could also have been applied. Using the above notation, this was equivalent to 
obtaining A x F x I for each subject and each gene. Finally, these attribute scores for each 
gene were combined into attribute scores for each gene set based on which genes were 
members of each set This resulted in a condensed dataset consisting of, for each subject, 
the aggregate scores for each attribute and gene set, denoted D above.  
As described previously, a weighted burden test can be carried out by performing a two 
sample t test to compare the risk score, R, between cases and controls (Curtis, 2012). In 
order to find a set of weights which best distinguishes cases from controls we can simply 
seek to maximise this t statistic. A program was written which would:  
(1) Read in the subject‑wise scores aggregated by attribute and gene set along with a 
set of weights for attributes and gene sets;  
(2) calculate the t statistic;  
(3) maximise the t statistic over different values for the weights using Powell's conjugate 
direction method, which does not require that a function be differentiable (Powell, 
1964).  
Powell's method was implemented using the dlib library (King, 2009). 
Model-fitting and cross-validation 
Initially, maximisation of the t statistic was carried out for the whole dataset for all 8 attribute 
weights and 36 gene set weights in order to find the best‑fitting values. For each weight a "1 
t confidence interval" was then defined as the range of values which could be assigned to 
that weight, keeping all other weights fixed, which would yield a t statistic no less than the 
maximum t statistic minus 1.  
To find a good‑fitting minimal set of weights a step‑wise procedure was followed. The weight 
for each attribute or gene set in turn was set to 0 and the t statistic was recalculated. If any 
produced a reduction in the t statistic to less than 1 below the original maximum the weight 
producing the smallest reduction was fixed at 0 and then the maximisation was repeated 
again over all the surviving weights. 
In order to assess the statistical significance of the fitted risk scores, a five‑way 
leave‑one‑out cross‑validation procedure was used. Maximisation to find the best‑fitting 
weights was carried out in a training four‑fifths of the dataset and then risk scores were 
calculated using these weights in the remaining test fifth. In addition, the t statistic which 
would have been obtained in the entire sample using these weights was calculated. This 
was repeated five times. The risk scores from each test fifth were then standardised by 
subtracting the mean and dividing by the standard deviation and then all five were combined 
and a t test was performed on the standardised risk scores for the whole sample.  
In order to assess the statistical significance of fitted risk scores derived from a minimal set 
of weights the step‑wise process described above was carried for each four‑fifths and then 
the weight obtained were used to calculate risk scores in the remaining fifth. Again, the 
combined, standardised risk scores obtained from the test subjects were then compared 
using a t test.  
The ability of the standardised risk scores in the test subjects to distinguish cases from 
controls was by calculating the receiver operating characteristic curve using the pROC 
package (Robin et al., 2011). 
The results are affected by the relative rather than absolute values of the weights, so in 
order to aid comparison of the results in the tables all the fitted weights were scaled so that 
the average magnitude for gene set weights and for the attribute weights would be 10. 
Results 
An unweighted analysis was performed by providing a weight of 1 for any gene and any 
variant with all other weights set to 0 and this produced a t statistic of 3.1. Fitting all gene set 
and attribute weights produced a maximised t statistic of 9.5 with the fitted values shown in 
Table 3. As can be seen, many weights had a wide confidence interval which included 0 and 
hence could be taken not to materially contribute to the fit. Applying the stepwise procedure 
to retain only important weights resulted in the minimal set also shown in Table 3. This 
includes weights for 8 out of the 32 gene sets and 3 of the attributes and with this reduced 
parameter set it was possible to produce a maximised t statistic of 8.6. The attributes with 
positive weights in this model were any variant, PolyPhen damaging and SIFT deleterious. 
The weights for both nonsynonymous and LOF could be set to 0, presumably because 
variants with this consequence could be adequately weighted using the SIFT and PolyPhen 
attributes. 
The weights fitted for each of the five training sets are shown in Table 4. Each set consists of 
a different four fifths of the dataset and hence they overlap with each other and the fitted 
weights they yield are similar though not identical. When the fitted weights were used to 
calculate a t statistic in the whole sample, the different training sets produced values ranging 
from 8.4 to 9.2, showing that each set of weights represented a solution reasonably close to 
the best attainable. The scores for the test samples in each fifth not used for training were 
standardised and combined and then a t test was performed comparing scores in cases and 
controls. This produced a t statistic of 3.3 with a p value of 0.001, demonstrating that the risk 
scores which are produced are indeed associated with risk of schizophrenia and are not 
simply an artefact of the fitting process. 
The fitted weights produced by applying the step‑wise procedure to each training set are 
shown in Table 5. It can be seen that there is considerable variation in the parameters 
retained. However the t statistics obtained for the whole sample using these weights varied 
between 7.4 and 8.3, showing that the different combinations of parameters selected were 
all able to produce risk scores which differed between cases and controls. When the 
standardised scores from the cases and controls not used for training were compared, the 
results were significant with a t statistic of 3.4 and a p value of 0.0006. Using either the full 
set of parameters or the minimal set, the ability of the risk score to distinguish cases from 
controls was extremely modest, with an area under the curve of only 0.52 in both situations. 
Thus, the minimal parameter sets found by the stepwise procedure result in risk scores 
which differ between cases from controls to a similar extent to the full set. The SIFT 
deleterious attribute is given a strong positive weight by all five training sets while PolyPhen 
damaging is used in two and LOF in one. The attribute for non‑coding effect has a small 
positive weight in three of the training sets. With respect to gene sets, in all training sets 
x.excape is given a large positive weight and pLI09 a small positive weight. These are the 
sets of genes which escape X inactivation and genes which are LOF intolerant. In four out of 
five training sets genes which are close to GWAS hits are given a strongly positive weight. 
Some gene sets are given negative weights. In four of the training sets dd, genes associated 
with developmental disability, is given a strongly negative weight and in two training sets the 
combined X‑linked disability is given a positive weight but subsets of X‑linked disability 
genes are weighted negatively. One way to interpret such findings is to view negative 
weights as encoding a "but not if " relationship. For example, "escapes X inactivation but not 
if associated with developmental disability". Of note is that there was no consistent retention 
of any of the gene sets which might be viewed as more specifically implicated in 
schizophrenia, such a de novo variants, or related to biology, such as neuronal, 
post‑synaptic density or NMDA receptor genes.   
Discussion 
The method presented here represents a first attempt to combine information from 
exome‑wide variants into a single risk score. The association of the score with the trait in test 
subjects is statistically significant although with minimal effect size. One possible explanation 
for this is that the gene sets used provide a poor categorisation of which genes do and do 
not influence risk of schizophrenia. If this is the case then one would hope that performance 
of the method would improve as more knowledge is accumulated to lead to better definition 
of risk genes. However an alternative explanation would be that some of the gene sets do 
indeed consist mostly of genes influencing risk but that the variation within these genes is so 
widespread that only a small minority of variants have an effect and that the scheme used 
here to categorise variant effects is unable to distinguish them. Again, as additional 
knowledge emerges it might be possible to devise improved classification schemes which 
would feed into an improved weighting system. 
The approach presented does provide a framework to systematically explore different kinds 
of contribution to risk. Given the complexity of the genetic architecture of schizophrenia, the 
sample sizes used here are too small for definite conclusions to be drawn but the results do 
illustrate the kind of inferences that could be made. For example, the results suggest that the 
SIFT prediction makes an important contribution to risk score but that other classifications do 
not provide much additional information. Likewise, the results suggest that genes which are 
loss of function intolerant, escape X inactivation or are implicated by a GWAS may be 
relevant to risk. However once these factors are taken into account the classifications which 
were chosen to reflect biological function do not appear to improve performance. The fact 
that some intellectual disability gene sets were given positive weights while others, including 
the genes for developmental disorder, were given negative weights hints at the notion that a 
subset of these genes influence schizophrenia risk and it is possible that one could use the 
risk score to explore this further. In general, the weighting of gene sets and variant attributes 
allows for a formal method to produce a summary risk score from all exome variants and to 
systematically explore the performance of different weighting schemes. 
The fact that all variant attributes and gene sets are considered jointly may provide this 
approach with some advantage of methods which dichotomise variants in different ways. 
There will be considerable sharing of attributes across variants and of genes across gene 
sets and the fitting method may allow better discrimination of the relevant influences on risk. 
For example, if two gene sets overlap then in a dichotomised analyses variants in both sets 
may show enrichment in cases. However if one set only shows enrichment by virtue of the 
fact that it contains many genes from the other set but provides no independent effect of its 
own then the fitted weight will tend to be zero. On the other hand, if both gene sets make an 
independent contribution then they may each receive a positive weight. 
A risk score from exome variants could be combined with a polygenic risk score from 
common SNPs. It could also be combined with risk scores derived from identified rare 
variants which have been shown to have a major effect on risk, such as specific copy 
number variants and gene mutations (Raychaudhuri et al., 2010; Singh et al., 2016). A 
recent study of autism has demonstrated that in subjects who possess rare variants having 
major effects on risk for autism, common variants can increase this risk further (Weiner et 
al., 2017). Likewise, environmental factors could be incorporated to provide an overall 
assessment of disease risk. 
The method as presented assumes that the cases and controls are drawn from the same 
population and does not include population principal components as covariates. Because it 
does not study individual variants but types of variant it may be relatively robust to 
differences in allele frequencies between sub‑populations. On the other hand, if there were 
among cases an over‑representation of a sub‑population in which there was a higher 
frequency in general of rare variants then this would produce false positive results. Hence it 
seemed important to exclude all subjects which appeared to have a substantial contribution 
of Finnish ancestry since otherwise the excess of Finnish alleles among cases would have 
been problematic. Given that the contribution to risk score seemed to be confined to 
particular gene sets and variant types, it seems that this procedure did result in an 
acceptably homogeneous dataset. 
The measure chosen to distinguish cases from controls was a weighted sum which could be 
used to obtain a t statistic. Other measures might be used, for example a log odds ratio 
which would fit into a logistic regression framework. The t statistic is very quick to calculate, 
which makes it attractive to use in the context of a maximisation process, and the risk score 
is simply a measure which increases with higher risk but which is not intended to provide a 
direct estimate of the actual quantitative risk of developing disease. The parameterisation of 
the model assumes that each type of variant affects each type of gene set equally. However 
more complex models could be developed, for example that loss of function variants in one 
set of genes increased risk but that for a different set of genes regulatory variants tended to 
be more important. Such models could be explored through machine learning techniques. 
Once a model had been developed using the general gene sets and variant types described 
above, it would be possible to try adding in additional genes or more specific gene sets in a 
systematic way in an effort to discover if any produced a significant improvement in the 
ability of the score to distinguish cases from controls. Such investigations will be the subject 
of subsequent work. 
The scheme proposed here represents a starting point for a method to summarise the 
genetic risk contribution of variation at the level of the whole exome. As it stands, it is able to 
produce risk scores which are significantly different between schizophrenia cases and 
controls and hopefully its performance could be improved with information from additional 
datasets, refinement of gene sets and with further modifications to the procedure. In principle 
it could be applied to any phenotype so that sets of relevant genes and the variants within 
them would be assigned weights designed to produce a score which correlated as closely as 
possible with the phenotype in question. 
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Table 1. Attributes ascribed to VEP annotation types. Each 1 indicates that the relevant 
attribute was assigned to the annotation. Three additional attributes were used. All variants 
were considered to have the "Any variant" attribute. Independent of their VEP annotation, 
variants could be classified as "Deleterious" by SIFT and variants could be classified as 





effect UTR Coding Non‑synonymous LOF 
NULL_CONSEQUENCE 
     intergenic_variant 
     feature_truncation 1 
    regulatory_region_variant 1 
    feature_elongation 1 
    regulatory_region_amplification 1 
    regulatory_region_ablation 1 
    TF_binding_site_variant 1 
    TFBS_amplification 1 
    TFBS_ablation 1 
    downstream_gene_variant 1 
    upstream_gene_variant 1 
    non_coding_transcript_variant 1 
    NMD_transcript_variant 1 
    intron_variant 1 
    non_coding_transcript_exon_variant 1 
    3_prime_UTR_variant 1 1 
   5_prime_UTR_variant 1 1 
   mature_miRNA_variant 1 
    coding_sequence_variant 
  
1 
  synonymous_variant 
  
1 
  stop_retained_variant 
  
1 
  incomplete_terminal_codon_variant 
  
1 
  splice_region_variant 
  
1 























1 1 1 
stop_gained 
  
1 1 1 
splice_donor_variant 
  
1 1 1 
splice_acceptor_variant 
  
1 1 1 
transcript_ablation 
  
1 1 1 
  
Table 2. Gene sets used in in the original analysis of this dataset which provides a full 
description of their derivation is in the online methods section (Genovese et al., 2016).  The 
lists were obtained directly from the first author. The symbol used is the same as that used 
for the name of the file containing the list. 
Gene set Symbol 
OMIM intellectual disability (Hamosh et al., 2005) alid 
Expression specific  to brain (Fagerberg et al., 2014) brain 
Bound by CELF4 (Wagnon et al., 2012) celf4 
Missense‑constrained (Samocha et al., 2014) constrained 
Involved in developmental disorder (Deciphering Developmental 
Disorders Study, 2017) 
dd 
De novo variants in autism (Fromer et al., 2014) denovo.aut 
De novo variants in coronary heart disease (Fromer et al., 2014) denovo.chd 
De novo variants in epilepsy (Fromer et al., 2014) denovo.epi 
De novo duplications in ASD (Kirov et al., 2012) denovo.gain.asd 
De novo duplications in bipolar disorder (Kirov et al., 2012) denovo.gain.bd 
De novo duplications in schizophrenia (Kirov et al., 2012) denovo.gain.scz 
De novo variants in intellectual disability (Fromer et al., 2014) denovo.id 
De novo deletions in ASD (Kirov et al., 2012) denovo.loss.asd 
De novo deletions in bipolar disorder (Kirov et al., 2012) denovo.loss.bd 
De novo deletions in schizophrenia (Kirov et al., 2012) denovo.loss.scz 
De novo variants in schizophrenia  (Fromer et al., 2014) denovo.scz 
Bound by FMRP (Darnell et al., 2011) fmrp 
Implicated by GWAS (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) 
gwas 
Targets of microRNA‑137 (Robinson et al., 2015) mir137 
Expression specific to neurons (Cahoy et al., 2008) neurons 
NMDAR and ARC complexes (Kirov et al., 2012) nmdarc 
Loss‑of‑function intolerant (Lek et al., 2016) pLI09 
PSD‑95 (Bayés et al., 2011) psd95 
Bound by RBFOX 1 or 3 (Weyn-Vanhentenryck et al., 2014) rbfox13 
Bound by RBFOX 2 (Weyn-Vanhentenryck et al., 2014) rbfox2 
Synaptic (Pirooznia et al., 2012) synaptome 
Escape X‑inactivation (Cotton et al., 2013) x.escape 
X‑linked intellectual disability, Genetic Services Laboratories of the 
University of Chicago (Gécz et al., 2009; Moeschler, 2008; 
Moeschler et al., 2006; Rauch et al., 2006) 
xlid.chicago 
X‑linked intellectual disability, Greenwood Genetic Centre 
(Moeschler et al., 2006) 
xlid.gcc 
X‑linked intellectual disability, OMIM (Hamosh et al., 2005) xlid.omim 
X‑linked intellectual disability (combined) xlid 
 
  
Table 3. Fitted weights chosen to maximise the t statistic for the risk score to distinguish 
cases from controls using all weights and using a minimal set of weights. The range 
indicates the values that the weight can take without reducing the t statistic to less than the 
maximum achieved minus 1. The minimal set of weights consists of those which are needed 
to produce a t statistic not less than the maximum minus 1. 





Gene sets   
alid 10.8  
(‑44.1,71.1) 
0 
brain ‑1.7  
(‑6.6,3.8) 
0 
celf4 ‑4.4  
(‑13.3,5.7) 
0 
constrained 2.4  
(‑12.1,21.5) 
0 




denovo.aut ‑0.1  
(‑4.2,5.2) 
0 




denovo.epi 1.2  
(‑14.1,19.3) 
0 
denovo.gain.asd ‑0.0  
(‑10.7,12.3) 
0 
denovo.gain.bd 7.3  
(‑26.8,48.0) 
0 
denovo.gain.scz ‑5.0  
(‑34.9,24.1) 
0 
denovo.id 1.1  
(‑6.2,9.4) 
0 
denovo.loss.asd 2.3  
(‑6.4,13.8) 
0 
denovo.loss.bd ‑7.5  
(‑55.8,52.0) 
0 




denovo.scz 0.1  
(‑6.0,6.8) 
0 
fmrp 0.5  
(‑6.2,9.2) 
0 




mir137 1.5  
(‑5.0,11.2) 
0 
neurons 2.8  
(‑4.3,13.1) 
0 
nmdarc 9.8  
(‑40.7,74.1) 
0 




psd95 ‑3.6  
(‑55.7,61.5) 
0 
rbfox13 ‑1.6  
(‑8.7,7.3) 
0 
rbfox2 0.6  
(‑6.7,10.1) 
0 












xlid.gcc 1.4  
(‑65.7,74.9) 
0 
xlid.omim ‑17.9  
(‑110.6,77.0) 
0 
xlid 30.1  
(‑23.6,95.6) 
0 
any gene 0.4  
(‑1.1,2.9) 
0 
Variant attributes   




non‑coding effect 4.5  
(‑1.1,16.2) 
0 
UTR ‑7.3  
(‑33.4,20.8) 
0 
coding 0.5  
(‑4.0,10.0) 
0 
nonsynonymous ‑0.8  
(‑9.2,18.4) 
0 
LOF 17.9  
(‑52.2,99.2) 
0 








   
t statistic achieved 9.5 8.6 
 
  
Table 4. Fitted weights chosen to maximise the t statistic in five training sets, each consisting 
of four fifths of the total sample. Also shown is the t statistic which is produced in the whole 
sample using that set of weights.  










Gene sets      
































































































































































































































































































































Variant attributes      


















































































      
t statistic in 
whole dataset 
8.8 8.4 9.2 8.8 8.7 
 
  
Table 5. Minimal set of weights for each training set. The weights are chosen to produce a t 
statistic not less than the maximum produced in the training set minus 1. Also shown is the t 
statistic produced in the whole dataset using the minimal set of weights. 
 Minimal 
weights 1  
(range) 
Minimal 
weights 2  
(range) 
Minimal 
weights 3  
(range) 
Minimal 
weights 4  
(range) 
Minimal 
weights 5  
(range) 
Gene sets      
alid 4.3  
(1.4,7.4) 
0 0 0 10.8  
(3.9,18.7) 
brain 0 ‑1.6  
(‑2.7,‑0.5) 
0 0 0 
celf4 ‑1.1  
(‑1.6,‑0.6) 
0 0 0 ‑3.2  
(‑4.5,‑1.9) 
constrained 0 0 0 0 0 
dd ‑8.2  
(‑11.3,‑5.3) 






denovo.aut 0 0 0 1.5  
(1.0,2.0) 
0 
denovo.chd 0 0 0 0 0 
denovo.epi 0 3.7  
(0.4,7.8) 
0 0 0 
denovo.gain.asd 0 0 0 0 0 
denovo.gain.bd 0 0 0 8.6  
(3.9,13.9) 
0 
denovo.gain.scz 0 0 0 0 0 
denovo.id 0 ‑1.6  
(‑3.1,‑0.1) 
0 0 0 
denovo.loss.asd 0 0 0 0 0 
denovo.loss.bd 0 0 0 0 0 





denovo.scz 0 0 0 ‑2.0  
(‑2.7,‑1.5) 
0 
fmrp 0 3.7  
(2.0,5.6) 
0 0 0 






0 14.5  
(8.0,21.6) 
mir137 0 0 0 0 0 
neurons 1.2  
(0.7,1.7) 
0 0 0 0 
nmdarc 0 0 0 18.6  
(9.1,29.5) 
0 










psd95 0 0 0 0 0 
rbfox13 0 0 0 0 0 
rbfox2 0 0 0 0 0 
synaptome 0 0 1.6  
(1.1,2.3) 
0 2.0  
(0.7,3.5) 










xlid.chicago ‑17.4  
(‑23.3,‑11.7) 
0 0 0 0 
xlid.gcc ‑14.2  
(‑18.2,‑10.1) 
0 ‑14.6  
(‑18.1,‑10.9) 
0 0 
xlid.omim ‑18.2  
(‑23.7,‑12.1) 
0 ‑19.9  
(‑24.6,‑15.2) 
0 0 
xlid 27.0  
(23.5,30.7) 
0 22.0  
(19.1,25.1) 
0 0 
any gene 0 0 0 0 0.7  
(0.4,1.0) 
Variant attributes      




0 0 0 
non‑coding effect 3.6  
(2.1,5.5) 
0 2.6  
(1.9,3.5) 
0 4.0  
(3.0,5.5) 
UTR 0 0 0 0 0 
coding 0 0 0 1.1  
(0.6,1.8) 
0 
nonsynonymous 0 6.7  
(0.8,21.0) 
0 0 0 
LOF 0 0 0 21.9  
(14.8,31.0) 
0 
PolyPhen damaging 0 0 9.8  
(5.8,15.2) 
0 12.8  
(7.9,20.1) 










      
t statistic in whole 
dataset 
8.2 7.4 8.2 8 8.3 
 
